Catalent eBook - 7
Novel Approaches to Improve Cell Therapy Manufacturing
understanding of regulatory requirements around
Paragon's deep experience in viral vector scale-up
handling human-sourced material, are critical to the
and production in combination with MaSTherCell's
success of these medicines. Coupled with supply
expertise in both autologous and allogeneic
chain complexity is the inherent challenge that each
cell therapy development and manufacturing
cell type has its unique biological blueprint making
allows Catalent to be a full-service global partner
it difficult to move towards a standardized manufac-
for advanced biotherapeutics. An outcome of
turing system for scalability. Even for gene therapies,
coupling these acquisitions with Catalent's broader
although adeno-associated virus (AAV) vectors
are leading the way, there are multiple options for
The growing gene therapy clinical
delivery, including lentiviruses, retroviruses and
pipeline is outpacing the available
others that require custom optimization. The burden
manufacturing capacity and
of continuous innovation for each project as well as
process expertise.
moving biological materials, like cells and viruses,
through each step of the operations exacerbates the
capabilities across the Biologics industry, is the ability
need for efficiency within the manufacturing process.
to extend our strategic partnerships and offer cross
Custom developers are better suited to manage
innovation with adjacent industries. The combined
this burden while balancing the complexities of the
strengths of Catalent and our strategic innovative
biological material.
partners allow for therapies to be manufactured
Catalent has made significant investments in
under high-quality standards and unmatched
the last year in cell and gene therapy with the
operational excellence in one of the fastest-growing
acquisitions of Paragon Bioservices and MaSTherCell.
areas of healthcare. n
Additional Content: Cell & Gene Therapy Manufacturing
Julien Meissonnier, Catalent's Vice President
and Chief Scientif ic Off icer, explores
strategies for alleviating cell and gene therapy
manufacturing bottlenecks to help achieve more
optimized and reproducible processes in this
on-demand webinar.
Download
GENengnews.com
|7
https://solutions.catalent.com/download_center?ContentID=1754
http://www.GENengnews.com
Catalent eBook
Table of Contents for the Digital Edition of Catalent eBook
Contents
Catalent eBook - 1
Catalent eBook - 2
Catalent eBook - 3
Catalent eBook - Contents
Catalent eBook - 5
Catalent eBook - 6
Catalent eBook - 7
Catalent eBook - 8
Catalent eBook - 9
Catalent eBook - 10
Catalent eBook - 11
Catalent eBook - 12
Catalent eBook - 13
Catalent eBook - 14
Catalent eBook - 15
Catalent eBook - 16
Catalent eBook - 17
Catalent eBook - 18
Catalent eBook - 19
Catalent eBook - 20
Catalent eBook - 21
Catalent eBook - 22
Catalent eBook - 23
Catalent eBook - 24
Catalent eBook - 25
Catalent eBook - 26
Catalent eBook - 27
Catalent eBook - 28
https://www.nxtbookmedia.com